World Health Organization & Gilead Sciences

World Health Organization: The World Health Organization is sponsoring and coordinating the clinical trial for Ebola treatments in the Democratic Republic of the Congo, aiming to find effective therapeutics for the Bundibugyo strain.

Gilead Sciences: Gilead Sciences is the developer of remdesivir, one of the antiviral drugs being evaluated in the clinical trial for Ebola. The company has donated doses of the drug for the study.

World Health Organization: The World Health Organization (WHO) has added the first molecular diagnostic test for Bundibugyo ebolavirus to its Emergency Use Listing, accelerating access to reliable diagnostic tools for early detection and response to the outbreak. WHO is a key player in coordinating global health responses and ensuring quality health products.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir is being evaluated in combination with Mapp Biopharmaceutical's MBP134 antibody in a treatment trial for the Bundibugyo Ebola outbreak.